Zhengye (ZYBT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$16.6M

Revenue (quarter)

$16.6M

Revenue growth (year over year)

−34.83%

Gross profit (trailing twelve months)

$3.4M

Gross margin

20.51%

Net income (trailing twelve months)

−$11.9M

Net income (quarter)

−$11.9M

Net income growth (year over year)

−742.92%

Net margin

−71.30%

Return on equity

−26.74%

EPS (trailing twelve months)

−$0.21

Book value per share

$0.75

P/E (trailing twelve months)

—

Price to book

1.09

Debt to assets

29.73%

Payout ratio

—

Dividend yield

—

Company profile

Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.

• Is Zhengye (ZYBT) profitable?

  No. Zhengye reported a net loss of $11.9M over the trailing twelve months.

• How much revenue does Zhengye (ZYBT) make?

  Zhengye generated $16.6M in revenue over the trailing twelve months, down 34.83% year over year.

• How do I buy stock in Zhengye (ZYBT)?

  ZYBT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.